LFG
GANX icon

Larson Financial Group’s Gain Therapeutics GANX Stock Holding History

Larson Financial Group’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20 Hold
10
– – ﹤0.01% 3718
2026
Q1 		$19 Hold
10
– – ﹤0.01% 3585
2025
Q4 		$32 Buy
+10
New +$27 ﹤0.01% 3401

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Larson Financial Group's GANX Position: Q2 2026 in Review

Larson Financial Group held its Gain Therapeutics (GANX) position steady in Q2 2026 at 10 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

Larson Financial Group first reported a position in GANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $32 in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Larson Financial Group held 10 shares of Gain Therapeutics worth $20 as of Q2 2026.
  • Larson Financial Group left its Gain Therapeutics share count unchanged in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3718 holding.
  • Larson Financial Group first reported a position in Gain Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Gain Therapeutics position peaked at $32 in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.